Basics ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. IPO Date: October 18, 2013 Sector: Healthcare Industry: Biotech Market Cap: $5.55B Activated in VL: True Average Daily Range Avg Daily Range: $0.15 | 2.80% Avg Daily Range (30 D): $0.62 | 3.06% Avg Daily Range (90 D): $0.51 | 2.78% Institutional Daily Volume Avg Daily Volume: 1.56M Avg Daily Volume (30 D): 3.53M Avg Daily Volume (90 D): 2.56M Trade Size Avg Trade Size (Sh.): 204 Avg Trade Size (Sh.) (30 D): 85 Avg Trade Size (Sh.) (90 D): 81 Institutional Trades Total Inst.Trades: 1,564 Avg Inst. Trade: $3.26M Avg Inst. Trade (30 D): $3.16M Avg Inst. Trade (90 D): $3.73M Avg Inst. Trade Volume: .33M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $4.9M Avg Closing Trade (30 D): $7.55M Avg Closing Trade (90 D): $8.51M Avg Closing Volume: 508.95K         News May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A Mar 4, 2025 @ 6:50 PM BREAKING: Block & Leviton Investigating ADMA Biolo... Source: Block & Leviton Nov 2, 2024 @ 10:18 AM BFA Law is Investigating ADMA BIOLOGICS for Securi... Source: N/A Oct 27, 2024 @ 12:06 PM ADMA FRAUD ALERT: BFA Law Notifies ADMA Biologics ... Source: N/A Financials   TTM Q4 2024 FY 2024 Basic EPS $.85 $.48 $.85 Diluted EPS $.81 $.46 $.81 Revenue $ 426.45M $ 117.55M $ 426.45M Gross Profit $ 219.55M $ 63.33M $ 219.55M Net Income / Loss $ 197.67M $ 111.9M $ 197.67M Operating Income / Loss $ 138.98M $ 38.32M $ 138.98M Cost of Revenue $ 206.9M $ 54.22M $ 206.9M Net Cash Flow $ 51.8M $ 16.44M $ 51.8M PE Ratio 26.60